00_preface_Cardiomyopathies - From Basic Research to Clinical Management......Page 1 00x_part1......Page 15 01_Classification and Definitions of Cardiomyopathies......Page 17 02_Management of Hypertrophic Obstructive Cardiomyopathy with a Focus on Alcohol Septal Ablation......Page 35 03_Hypertrophic Cardiomyopathy in Infants and Children......Page 47 04_Quality of Life in Dilated Cardiomyopathy with Refractory Chronic Heart Failure Undergoing Devices Implantation......Page 83 05_Peripartum Cardiomyopathy: A Systematic Review......Page 97 06_Cardiomyopathy Detection from Electrocardiogram Features......Page 131 07_Prevention of Sudden Cardiac Death in Patients with Cardiomyopathy......Page 149 08_Biomarker for Cardiomyopathy-B-Type Natriuretic Peptide......Page 181 08x_part2......Page 197 09_Heart Muscle and Apoptosis......Page 199 10_Cardiac Myocytes and Mechanosensation......Page 215 11_Dobutamine-Induced Mechanical Alternans......Page 227 12_MicroRNAs Telltale Effects on Signaling Networks in Cardiomyopathy......Page 237 13_Intercellular Connections in the Heart: The Intercalated Disc......Page 259 14_Familial Hypertrophic Cardiomyopathy-Related Troponin Mutations and Sudden Cardiac Death......Page 291 15_Consequences of Mutations in Genes Encoding Cardiac Troponin C, T and I – Molecular Insights......Page 317 16_ Cardiomyopathies Associated with Myofibrillar Myopathies......Page 367 17_Functional Consequences of Mutations in the Myosin Regulatory Light Chain Associated with Hypertrophic Cardiomyopathy......Page 397 18_Role of Genetic Factors in Dilated Cardiomyopathy......Page 423 18x_part3......Page 437 19_Role of Advanced Cardiac Magnetic Resonance Imaging in Atypical Cardiomyopathies such as Stress-Induced Cardiomyopathie and Left-Ventricular Non-Compaction Cardiomyopathy......Page 439 20_The Use of Contrast-Enhancement Cardiovascular Magnetic Resonance Imaging in Cardiomyopathies......Page 453 20x_part4......Page 475 21_The Evolving Face of Heart Failure Associated with Elevated Cardio-Metabolic Risk Factors......Page 477 22_Diabetic Cardiomyopathy: Cardiac Changes, Pathophysiological Mechanisms, Biologic Markers, and the Available Therapeutic Armamentarium......Page 501 23_Insulin Resistance and Cardiomyopathy......Page 527 24_Taurine Depletion-Related Cardiomyopathy in Animals......Page 551 25_Thyrotoxic Cardiomyopathy......Page 567 26_Drug-Induced Cardiomyopathies......Page 595 27_Anthracycline Cardiotoxicity......Page 635 28_Cardiotonic Steroids and Cardiac Fibrosis......Page 659 28x_part5......Page 677 29_Stress-Induced Cardiomyopathy: Clinical Observations......Page 679 30_Takotsubo Cardiomyopathy......Page 697 31_Pathology of Takotsubo (Ampulla) Cardiomyopathy......Page 723 32_Torsades de Pointes in Takotsubo Cardiomyopathy with QT Prolongation......Page 741 33_Torsades de Pointes Associated with Takotsubo Cardiomyopathy: Is It Preventable?......Page 751 33x_part6......Page 761 34_Chagas Heart Disease......Page 763 35_Chagasic Cardiomyopathy ......Page 789 Cardiomyopathy means "heart (cardio) muscle (myo) disease (pathy)". Currently, cardiomyopathies are defined as myocardial disorders in which the heart muscle is structurally and/or functionally abnormal in the absence of a coronary artery disease, hypertension, valvular heart disease or congenital heart disease sufficient to cause the observed myocardial abnormalities. This book provides a comprehensive, state-of-the-art review of the current knowledge of cardiomyopathies. Instead of following the classic interdisciplinary division, the entire cardiovascular system is presented as a functional unity, and the contributors explore pathophysiological mechanisms from different perspectives, including genetics, molecular biology, electrophysiology, invasive and non-invasive cardiology, imaging methods and surgery. In order to provide a balanced medical view, this book was edited by a clinical cardiologist
